An article from NBC News highlights a new treatment for triple-negative breast cancer. A new vaccine in Phase 1 trial is sparking hope for women.
From NBC News:
Breast cancer treatment is determined in part by whether certain proteins are present on the tumor cells, including estrogen receptors and progesterone receptors, as well as a protein called HER2. Treatments can target these three proteins. Breast cancers with neither receptor and which produce little to no HER2 are deemed triple-negative, making them more difficult to treat.
The article records Chase Johnson‘s participation in the trial. NBC explains:
In December 2022, Johnson enrolled in an early-stage clinical trial at the Cleveland Clinic that is testing a novel vaccine that researchers hope could stop triple-negative breast cancer recurrences and, in some women, stop the cancer from developing in the first place.
The vaccine targets a protein called α-lactalbumin, which is present in about 70% of triple-negative breast cancers and found on the surface of tumor cells. If successful, the vaccine would teach the immune system to make T-cells that attack and destroy cells with the protein.
On Thursday, the findings of the Phase 1 clinical trial of 35 women were presented at the San Antonio Breast Cancer Symposium in Texas.
While the trial did not look at how the vaccine affected outcomes, it did study the vaccine’s safety and the participant’s immune response. After studying three different groups of women, researchers found that 74% of the women developed an immune response to the vaccine. Scientists don’t know if it will reduce recurrence or prevent the disease.
Triple-negative breast cancer vaccine shows promise in early clinical trial. https://t.co/5ZQZHDFhhR
— NBC News (@NBCNews) December 12, 2025
Read more at NBC News
The Dennis Michael Lynch Podcast archive is available below, with the most recent on top. Never miss an episode. Subscribe to the show by downloading The DML News App or go to Apple Podcasts.
